RxDoctor Payments Data

Pushpa Reddy, MD

Internal Medicine · Webster, TXNPI 1780766030

Payments from drug & device makers

$1,040in general payments, 2019–2025

Across 51 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$243
  • Amgen$146
  • AbbVie$140
  • Astellas Pharma US Inc$97
  • Lilly USA, LLC$74
  • GSK$72
  • plus $269 from 9 others

What the payments were for

  • Food & beverage$1,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,040 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$204,553
Medicare patients
120
Services billed
3,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$107,596
JanuviaSitagliptin Phosphate45$59,003
RybelsusSemaglutide20$36,433
TrulicityDulaglutide23$36,174
MounjaroTirzepatide35$35,061
JanumetSitagliptin Phos/Metformin Hcl23$29,644
Tresiba Flextouch U-200Insulin Degludec19$24,484
FarxigaDapagliflozin Propanediol21$16,099
JardianceEmpagliflozin13$16,056
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,481
Soliqua 100-33Insulin Glargine/Lixisenatide16$12,797
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$9,281
MyrbetriqMirabegron13$7,443
Breo ElliptaFluticasone/Vilanterol16$6,512
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$243$144,029123 claims
Lilly USA, LLCTrulicity, Mounjaro$74$71,23558 claims
GSKTrelegy Ellipta, Breo Ellipta$72$19,99336 claims
AstraZenecaFarxiga$62$16,09921 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$39$12,79716 claims
Astellas Pharma US IncMyrbetriq$97$7,44313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →